HOTH
$1.04
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
Intraday
Recent News
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.5% and the S
2 Stocks to Buy Under $10 That Wall Street Loves
While penny stocks are risky, they also have the potential to deliver outsized gains.
NVDA: Nvidia Stock Breaks New Record After Cantor Hikes Price Target to $300
Nvidia Rally Deepens as Investors Bet on AI Expansion and Strong Guidance
Hoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin Therapy
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Hoth Therapeutics, Inc. is one of them. Hoth Therapeutics, Inc. (NASDAQ:HOTH) is advancing next-generation therapies across dermatology, oncology, and neurology, with a robust pipeline that includes proprietary platforms like BioLexa for antimicrobials and HT-ALZ […]
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers
Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday announced combined findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT. HT-KIT is a precision antisense oligonucleotide designed to silence mutant KIT mRNA, an oncogenic driver in gastrointestinal stromal tumors (GIST), systemic mastocytosis, and certain leukemias. Preclinical Efficacy & Safety Highlights HT-KIT triggered significant tumor cell death in preclinical models of gastrointestinal stromal tumor